Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06321107
Active, not recruiting Observational

Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference

NCT06321107 · tracked via the Priya Life Science China tracker
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd
Phase
Observational
Started
2024-03-01
Last updated
2025-04-08

Condition(s) studied

Infertility

Study summary

The purpose of this study is to evaluate the safety of a single injection of GenSci094 during Controlled Ovarian Stimulation up to 1 year old of the infants from previous studies.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
39 Years
Healthy volunteers
No
Inclusion Criteria: 1. Willing and able to sign informed consent 2. Subjects who participated in Phase II or Phase III clinical trial of GenSci094 and received at least one treatment with GenSci094 or Gonal-F ® 3. Subjects who indentified an ongoing pregnancy in Phase II or Phase III clinical trial of GenSci094 Exclusion Criteria: NA

Primary outcome measure(s)

  • Summary of Pregnancy Outcome — To be assessed at late abortion or birth (up to 10 months)
    Pregnancy outcomes were reported at the optional long-term follow up visit.

Trial sites (1)

FacilityCityRegionStatus
The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital Guangzhou Guangdong

More Changchun GeneScience Pharmaceutical Co., Ltd. trials in China

Phase 1 Clinical Study of GenSci164 Injection Starting soon
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis Starting soon
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. Recruiting
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia Recruiting
Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Recruiting

Other trials for the same condition

Microfluidic Chip vs Density Gradient Centrifugation on the Euploidy Rate of Pre-implantation Genetic Testing Recruiting
Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility Recruiting
Standardization and Application of Pure Platelet-Rich Plasma in Improving Sperm Function Starting soon
Clinical Evaluation of Integrated Chinese-Western Medicine for Infertility With DOR Patients in Women Achieving Natural Pregnancy Starting soon
Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06321107 on ClinicalTrials.gov ↗ ← All trials in China